Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Cort, Aysegul ^a   Ozben, Tomris ^b   Saso, Luciano ^c   De Luca, Chiara ^d   Korkina, Liudmila ^e  

^a SANKO UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Evidence Based Well Being Ltd   (Germany)

^e Centre of Innovative Biotechnological Investigations Nanolab   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; DRUG PRODUCTS; ENZYMES; METABOLISM; MOUNTINGS; REDOX REACTIONS; TUMORS;

ADAPTIVE MECHANISM; ANTI-CANCER CHEMOTHERAPY; ANTI-OXIDANT RESPONSE; ANTIOXIDANT DEFENCE; ANTIOXIDANT ENZYME; METABOLIC ENZYMES; METABOLIC TRANSFORMATIONS; MULTIDRUG RESISTANCE;

ANTIOXIDANTS;

ABC TRANSPORTER; ALDEHYDE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; AROMATIC HYDROCARBON RECEPTOR; HYDROPEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INOSITOL PHOSPHATE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; TOXIN; TRANSCRIPTION FACTOR NRF2; ABCB1 PROTEIN, HUMAN; CYTOCHROME P450; GLUTATHIONE; HYDROGEN PEROXIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; NFE2L2 PROTEIN, HUMAN; P-GLYCOPROTEIN 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

CANCER CHEMOTHERAPY; DNA POLYMORPHISM; DRUG ELIMINATION; DRUG METABOLISM; GENE OVEREXPRESSION; GLUTATHIONE METABOLISM; HOST; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; REDOX STRESS; REVIEW; SIGNAL TRANSDUCTION; STRESS; TARGET CELL; TUMOR CELL; UPREGULATION; APOPTOSIS; CHEMISTRY; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; OXIDATION REDUCTION REACTION;

ALDEHYDES; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; HYDROGEN PEROXIDE; INFLAMMATION; NADPH OXIDASE; NEOPLASMS; NF-E2-RELATED FACTOR 2; NF-KAPPA B; OXIDATION-REDUCTION; P-GLYCOPROTEINS; REACTIVE OXYGEN SPECIES; RECEPTORS, ARYL HYDROCARBON; SIGNAL TRANSDUCTION;

EID: 84961320061     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/4251912     Document Type: Review

References (190)

1. M. T. Kuo, Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities, Antioxidants and Redox Signaling, vol. 11, no. 1, pp. 99-133, 2009.
2. S. Shukla, S. Ohnuma, and S. V. Ambudkar, Improving cancer chemotherapy with modulators of ABC drug transporters, Current Drug Targets, vol. 12, no. 5, pp. 621-630, 2011.
3. W. W. Ma and A. A. Adjei, Novel agents on the horizon for cancer therapy, CA: A Cancer Journal for Clinicians, vol. 59, no. 2, pp. 111-137, 2009.
4. T. Nakanishi and D. D. Ross, Breast cancer resistance protein (BCRP/ABCG2): its role inmultidrug resistance and regulation of its gene expression, Chinese Journal of Cancer, vol. 31, no. 2, pp. 73-99, 2012.
5. J. V. Goldstone, A. Hamdoun, B. J. Cole et al. , The chemical defensome: environmental sensing and response genes in the Strongylocentrotus purpuratus genome, Developmental Biology, vol. 300, no. 1, pp. 366-384, 2006.
6. L. Korkina, M. G. Scordo, I. Deeva, E. Cesareo, and C. De Luca, The chemical defensive system in the pathobiology of idiopathic environment-associated diseases, Current Drug Metabolism, vol. 10, no. 8, pp. 914-931, 2009.
7. S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan, andM. M. Gottesman, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annual Review of Pharmacology and Toxicology, vol. 39, pp. 361-398, 1999.
8. S. P. C. Cole and R. G. Deeley, Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP, BioEssays, vol. 20, no. 11, pp. 931-940, 1998.
9. B. Sarkadi, C. Ozvegy-Laczka, K. Német, and A. Váradi, ABCG2-a transporter for all seasons, FEBS Letters, vol. 567, no. 1, pp. 116-120, 2004.
10. M. S. Denison and S. R. Nagy, Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals, Annual Review of Pharmacology and Toxicology, vol. 43, pp. 309-334, 2003.
11. P. Pavek and Z. Dvorak, Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 super-family in human extrahepatic tissues, Current Drug Metabolism, vol. 9, no. 2, pp. 129-143, 2008.
12. D. Kluth, A. Banning, I. Paur, R. Blomhoff, and R. Brigelius-Flohé, Modulation of pregnane X receptor-and electrophile responsive element-mediated gene expression by dietary polyphenolic compounds, Free Radical Biology and Medicine, vol. 42, no. 3, pp. 315-325, 2007.
13. K. W. Bock and C. Köhle, Coordinate regulation of drug metabolism by xenobiotic nuclear receptors: UGTs acting together with CYPs and glucuronide transporters, DrugMetabolism Reviews, vol. 36, no. 3-4, pp. 595-615, 2004.
14. C. D. Klaassen and A. L. Slitt, Regulation of hepatic transporters by xenobiotic receptors, Current DrugMetabolism, vol. 6, no. 4, pp. 309-328, 2005.
15. T. Nguyen, P. J. Sherratt, and C. B. Pickett, Regulatory mechanisms controlling gene expression mediated by the antioxidant response element, Annual Review of Pharmacology and Toxicology, vol. 43, pp. 233-260, 2003.
16. A. K. Jaiswal, Nrf2 signaling in coordinated activation of antioxidant gene expression,FreeRadical BiologyandMedicine, vol. 36, no. 10, pp. 1199-1207, 2004.
17. B. Fadeel and S. Orrenius, Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease, Journal of Internal Medicine, vol. 258, no. 6, pp. 479-517, 2005.
18. L. Góth, P. Rass, and A. Páy, Catalase enzyme mutations and their association with diseases, Molecular Diagnosis, vol. 8, no. 3, pp. 141-149, 2004.
19. J. G. Scandalios, Oxidative stress: Molecular perception and transduction of signals triggering antioxidant gene defenses, Brazilian Journal ofMedical and Biological Research, vol. 38, no. 7, pp. 995-1014, 2005.
20. A. Bindoli and M. P. Rigobello, Principles in redox signaling: from chemistry to functional significance, Antioxidants & Redox Signaling, vol. 18, no. 13, pp. 1557-1593, 2013.
21. A. Ayala, M. F. Munoz, and S. Arguelles, Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal, Oxidative Medicine and Cellular Longevity, vol. 2014,Article ID 360438, 31 pages, 2014.
22. C. M. Cabello,W. B. Bair III, and G. T. Wondrak, Experimental therapeutics: targeting the redox Achilles heel of cancer, Current Opinion in Investigational Drugs, vol. 8, no. 12, pp. 1022-1037, 2007.
23. G. T. Wondrak, Redox-directed cancer therapeutics:molecular mechanisms and opportunities, Antioxidants and Redox Signaling, vol. 11, no. 12, pp. 3013-3069, 2009.
24. L. G. Korkina, S. Pastore, C. De Luca, and V. A. Kostyuk, Metabolism of plant polyphenols in the skin: beneficial versus deleterious effects, Current Drug Metabolism, vol. 9, no. 8, pp. 710-729, 2008.
25. F. Oesch, E. Fabian, B. Oesch-Bartlomowicz, C. Werner, and R. Landsiedel, Drug-metabolizing enzymes in the skin of man, rat, and pig, Drug Metabolism Reviews, vol. 39, no. 4, pp. 659-698, 2007.
26. A. Cort and T. Ozben, Natural product modulators to overcomemultidrug resistance in cancer,Nutrition and Cancer, vol. 67, no. 3, pp. 411-423, 2015.
27. P. Anand,A. B. Kunnumakkara, R. A. Newman, B. B. Aggarwal, Bioavailability of curcumin: problems and promises, Molecular Pharmaceutics, vol. 4, no. 6, pp. 807-818, 2007.
28. J. D. Lambert, S. Sang, A. Y. H. Lu, and C. S. Yang, Metabolism of dietary polyphenols and possible interactions with drugs, Current Drug Metabolism, vol. 8, no. 5, pp. 499-507, 2007.
29. R. Cermak, Effect of dietary flavonoids on pathways involved in drug metabolism, Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 1, pp. 17-35, 2008.
30. S. Muranaka, H. Fujita, T. Fujiwara et al. , Mechanism and characteristics of stimuli-dependent ROS generation in undifferentiated HL-60 cells, Antioxidants and Redox Signaling, vol. 7, no. 9-10, pp. 1367-1376, 2005.
31. J. Axelrod and R. Tomchick, Enzymatic O-methylation of epinephrine and other catechols, The Journal of Biological Chemistry, vol. 233, no. 3, pp. 702-705, 1958.
32. R. S. Rapaka and P. M. Coates, Dietary supplements and related products: a brief summary, Life Sciences, vol. 78, no. 18, pp. 2026-2032, 2006.
33. D. Pal and A. K. Mitra, MDR-and CYP3A4-mediated drugherbal interactions, Life Sciences, vol. 78, no. 18, pp. 2131-2145, 2006.
34. D. Li, A. Abudula, M. Abulahake, A. -P. Zhu, Y. -Q. Lou, and G. -L. Zhang, Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 -hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese, Journal of Clinical Pharmacology, vol. 50, no. 7, pp. 775-784, 2010.
35. V. J. Victorino, L. Pizzatti, P. Michelletti, and C. Panis, Oxidative stress, redox signaling and cancer chemoresistance: putting together the pieces of the puzzle, CurrentMedicinal Chemistry, vol. 21, no. 28, pp. 3211-3226, 2014.
36. L. E. Tebay, H. Robertson, S. T. Durant et al. , Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease, Free Radical Biology & Medicine, vol. 88, pp. 108-146, 2015.
37. K. Aoyama and T. Nakaki, Glutathione in cellular redox homeostasis: association with the excitatory amino acid carrier 1 (EAAC1), Molecules, vol. 20, no. 5, pp. 8742-8758, 2015.
38. H. F. Gilbert, Thiol/disulfide exchange equilibria and disulfide bond stability,Methods in Enzymology, vol. 251, pp. 8-28, 1995.
39. G. M. Cunningham, M. G. Roman, L. C. Flores et al. , The paradoxical role of thioredoxin on oxidative stress and aging, Archives of Biochemistry and Biophysics, vol. 576, pp. 32-38, 2015.
40. A. Perkins, L. B. Poole, and P. A. Karplus, Tuning of peroxiredoxin catalysis for various physiological roles, Biochemistry, vol. 53, no. 49, pp. 7693-7705, 2014.
41. Y. Hirotsu, F. Katsuoka, R. Funayama et al. , Nrf2-MafG heterodimers contribute globally to antioxidant and metabolic networks, Nucleic Acids Research, vol. 40, no. 20, pp. 10228-10239, 2012.
42. D. T. Lincoln, E. M. Ali Emadi, K. F. Tonissen, and F. M. Clarke, The thioredoxin-thioredoxin reductase system: over-expression in human cancer, Anticancer Research, vol. 23, no. 3, pp. 2425-2433, 2003.
43. S. J. Kim, Y. Miyoshi, T. Taguchi et al. , High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer, Clinical Cancer Research, vol. 11,no. 23,pp. 8425-8430, 2005.
44. C. Li, M. A. Thompson, A. T. Tamayo et al. , Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma, Oncotarget, vol. 3, no. 3, pp. 314-326, 2012.
45. B. Zhang, C. Xie, J. Zhong, H. Chen, H. Zhang, and X. Wang, A549 cell proliferation inhibited by RNAi mediated silencing of the Nrf2 gene, Bio-Medical Materials and Engineering, vol. 24, no. 6, pp. 3905-3916, 2014.
46. P. V. Raninga, G. Di Trapani, S. Vuckovic, M. Bhatia, and K. F. Tonissen, Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma, Oncotarget, vol. 6, no. 17, pp. 15410-15424, 2015.
47. Y. Tan, L. Bi, P. Zhang et al. , Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide, International Journal of Clinical and Experimental Pathology, vol. 7, no. 8, pp. 4765-4773, 2014.
48. F. Wang, F. Lin, P. Zhang et al. , Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines, Oncology Reports, vol. 33, no. 2, pp. 967-973, 2015.
49. B. R. You, H. R. Shin, andW. H. Park, PX-12 inhibits the growth of A549 lung cancer cells via G2/M phase arrest and ROSdependent apoptosis, International Journal ofOncology, vol. 44, no. 1, pp. 301-308, 2014.
50. J. -J. Liu, Q. Liu, H. -L. Wei, J. Yi, H. -S. Zhao, and L. -P. Gao, Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronicmyeloid leukemia cells, Die Pharmazie, vol. 66,no. 6, pp. 440-444, 2011.
51. W. Fiskus, N. Saba, M. Shen et al. , Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia, Cancer Research, vol. 74, no. 9, pp. 2520-2532, 2014.
52. N. Park and Y. -J. Chun, Auranofin promotes mitochondrial apoptosis by inducing annexin A5 expression and translocation in human prostate cancer cells, Journal of Toxicology and Environmental Health-Part A: Current Issues, vol. 77, no. 22-24, pp. 1467-1476, 2014.
53. N. -H. Kim, H. J. Park, M. -K. Oh, and I. -S. Kim, Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells, BMB Reports, vol. 46, no. 1, pp. 59-64, 2013.
54. R. Kannappan, V. R. Yadav, and B. B. Aggarwal, -tocotrienol but not -tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents, The Journal of Biological Chemistry, vol. 285, no. 43, pp. 33520-33528, 2010.
55. M. F. McCarty, J. Barroso-Aranda, and F. Contreras, A twophase strategy for treatment of oxidant-dependent cancers, Medical Hypotheses, vol. 69, no. 3, pp. 489-496, 2007.
56. J. Wang, W. Guo, H. Zhou et al. , Mitochondrial p53 phosphorylation induces Bak-mediated and caspase-independent cell death, Oncotarget, vol. 6, no. 19, pp. 17192-17205, 2015.
57. L. M. Shelton, B. K. Park, and I. M. Copple, Role of Nrf2 in protection against acute kidney injury, Kidney International, vol. 84, no. 6, pp. 1090-1095, 2013.
58. C. -P. Wu, S. Ohnuma, and S. V. Ambudkar, Discovering natural productmodulators to overcomemultidrug resistance in cancer chemotherapy, Current Pharmaceutical Biotechnology, vol. 12, no. 4, pp. 609-620, 2011.
59. V. Stepanic,A. Gasparovic, K. Troselj,D. Amic, andN. Zarkovic, Selected attributes of polyphenols in targeting oxidative stress in cancer, Current Topics in Medicinal Chemistry, vol. 15, no. 5, pp. 496-509, 2015.
60. S. Y. Shin, H. Jung, S. Ahn et al. , Polyphenols bearing cinnamaldehyde scaffold showing cell growth inhibitory effects on the cisplatin-resistant A2780/Cis ovarian cancer cells, Bioorganic & Medicinal Chemistry, vol. 22, no. 6, pp. 1809-1820, 2014.
61. I. Akan, S. Akan, H. Akca, B. Savas, and T. Ozben, Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine, Cancer Cell International, vol. 5, no. 1, article 22, 2005.
62. I. Akan, S. Akan, H. Akca, B. Savas, and T. Ozben, N-acetylcysteine enhances multidrug resistance-associated protein 1 mediated doxorubicin resistance, European Journal of Clinical Investigation, vol. 34, no. 10, pp. 683-689, 2004.
63. M. Yildiz, C. Celik-Ozenci, S. Akan et al. , Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: an in vitro study, Cell Biology International, vol. 30, no. 3, pp. 278-282, 2006.
64. M. Benlloch, A. Ortega, P. Ferrer et al. , Acceleration of glutathione efflux and inhibition of -glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity, The Journal of Biological Chemistry, vol. 280, no. 8, pp. 6950-6959, 2005.
65. N. Traverso, R. Ricciarelli, M. Nitti et al. , Role of glutathione in cancer progression and chemoresistance, OxidativeMedicine and Cellular Longevity, vol. 2013, Article ID 972913, 10 pages, 2013.
66. K. Itoh, T. Chiba, S. Takahashi et al. , An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements, Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 313-322, 1997.
67. P. Krishnamurthy and J. D. Schuetz, Role of ABCG2/BCRP in biology and medicine, Annual Review of Pharmacology and Toxicology, vol. 46, pp. 381-410, 2006.
68. K. Noguchi, K. Katayama, and Y. Sugimoto, Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics, Pharmacogenomics and Personalized Medicine, vol. 7, no. 1, pp. 53-64, 2014.
69. C. Jacob, V. Jamier, and L. A. Ba, Redox active secondary metabolites, Current Opinion in Chemical Biology, vol. 15, no. 1, pp. 149-155, 2011.
70. F. Q. Schafer and G. R. Buettner, Redox environment of the cell as viewed through the redox state of the glutathione disulfide/ glutathione couple, Free Radical Biology andMedicine, vol. 30, no. 11, pp. 1191-1212, 2001.
71. A. G. Blazquez, O. Briz, E. Gonzalez-Sanchez, M. J. Perez, C. I. Ghanem, and J. J. G. Marin, The effect of acetaminophen on the expression of BCRP in trophoblast cells impairs the placental barrier to bile acids duringmaternal cholestasis, Toxicology and Applied Pharmacology, vol. 277, no. 1, pp. 77-85, 2014.
72. S. V. Iverson, S. Eriksson, J. Xu et al. , A Txnrd1-dependent metabolic switch alters hepatic lipogenesis, glycogen storage, and detoxification, Free Radical Biology and Medicine, vol. 63, pp. 369-380, 2013.
73. T. W. Young, F. C. Mei, G. Yang, J. A. Thompson-Lanza, J. Liu, and X. Cheng, Activation of antioxidant pathways in rasmediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry, Cancer Research, vol. 64, no. 13, pp. 4577-4584, 2004.
74. D. -Y. Lee and G. -D. Chang, Methylglyoxal in cells elicits a negative feedback loop entailing transglutaminase 2 and glyoxalase 1, Redox Biology, vol. 2, no. 1, pp. 196-205, 2014.
75. P. Agostinis,K. Berg, K. A. Cengel et al. , Photodynamic therapy of cancer: an update, CA: A Cancer Journal for Clinicians, vol. 61, no. 4, pp. 250-281, 2011.
76. B. Krammer and T. Verwanger, Molecular response to hypericin-induced photodamage, Current Medicinal Chemistry, vol. 19, no. 6, pp. 793-798, 2012.
77. L. Mike?sová, J. Mike?s, J. Koval et al. , Conjunction of glutathione level, NAD(P)H/FAD redox status and hypericin content as a potential factor affecting colon cancer cell resistance to photodynamic therapy with hypericin, Photodiagnosis and Photodynamic Therapy, vol. 10, no. 4, pp. 470-483, 2013.
78. J. -H. Kim, C. Chen, and A. -N. Tony Kong, Resveratrol inhibits genistein-induced multi-drug resistance protein 2 (MRP2) expression in HepG2 cells, Archives of Biochemistry and Biophysics, vol. 512, no. 2, pp. 160-166, 2011.
79. M. A. Valentovic, J. G. Ball, J. M. Brown et al. , Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress, Toxicology in Vitro, vol. 28, no. 2, pp. 248-257, 2014.
80. D. -J. Tai, W. -S. Jin, C. -S. Wu et al. , Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells, Experimental and Therapeutic Medicine, vol. 4, no. 2, pp. 291-296, 2012.
81. A. Manna, A. K. Bauri, S. Chattopadhyay, and M. Chatterjee, Generation of redox imbalancemediates the cytotoxic effect of Malabaricone-A in a multidrug resistant cell line, Anti-Cancer Agents inMedicinal Chemistry, vol. 15, no. 9, pp. 1156-1163, 2015.
82. K. Bedard and K. -H. Krause, The NOX family of ROSgeneratingNADPHoxidases: physiology and pathophysiology, Physiological Reviews, vol. 87, no. 1, pp. 245-313, 2007.
83. K. A. Graham, M. Kulawiec, K. M. Owens et al. , NADPH oxidase 4 is an oncoprotein localized to mitochondria, Cancer Biology & Therapy, vol. 10, no. 3, pp. 223-231, 2010.
84. R. Wang, W. -M. Dashwood, H. Nian et al. , NADPH oxidase overexpression in human colon cancers and rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), International Journal of Cancer, vol. 128, no. 11, pp. 2581-2590, 2011.
85. B. M. Barth, S. Stewart-Smeets, and T. B. Kuhn, Proinflammatory cytokines provoke oxidative damage to actin in neuronal cells mediated by Rac1 and NADPH oxidase, Molecular and Cellular Neuroscience, vol. 41, no. 2, pp. 274-285, 2009.
86. B. M. Barth, S. J. Gustafson, M. M. Young et al. , Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance, Cancer Biology & Therapy, vol. 10, no. 11, pp. 1126-1136, 2010.
87. J. Su, Y. Xu, L. Zhou et al. , Suppression of chloride channel 3 expression facilitates sensitivity of human glioma U251 cells to cisplatin through concomitant inhibition of Akt and autophagy, Anatomical Record, vol. 296, no. 4, pp. 595-603, 2013.
88. M. C. E. McFadyen, W. T. Melvin, and G. I. Murray, Cytochrome P450 enzymes: novel options for cancer therapeutics, Molecular CancerTherapeutics, vol. 3, no. 3, pp. 363-371, 2004.
89. T. Oyama, N. Kagawa, N. Kunugita et al. , Expression of cytochrome P450 in tumor tissues and its association with cancer development, Frontiers in Bioscience, vol. 9, pp. 1967-1976, 2004.
90. D. W. Nebert and D. W. Russell, Clinical importance of the cytochromes P450,TheLancet, vol. 360, no. 9340, pp. 1155-1162, 2002.
91. X. Ding and L. S. Kaminsky, Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts, Annual Reviewof Pharmacology and Toxicology, vol. 43,pp. 149-173, 2003.
92. D. Molina-Ortiz, R. Camacho-Carranza, J. F. González-Zamora et al. , Differential expression of cytochrome P450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma, PLoS ONE, vol. 9, no. 4,Article ID e93261, 2014.
93. K. M. Marks, E. S. Park, A. Arefolov et al. , The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes, Journal of Natural Products, vol. 74, no. 4, pp. 567-573, 2011.
94. D. J. Taxman, J. P. MacKeigan,C. Clements,D. T. Bergstralh, and J. P. -Y. Ting, Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogenactivated protein/extracellular signal-regulated kinase kinase inhibitor, Cancer Research, vol. 63, no. 16, pp. 5095-5104, 2003.
95. S. Reuter, S. C. Gupta, M. M. Chaturvedi, and B. B. Aggarwal, Oxidative stress, inflammation, and cancer: how are they linked? Free Radical Biology and Medicine, vol. 49, no. 11, pp. 1603-1616, 2010.
96. L. M. Coussens and Z. Werb, Inflammation and cancer, Nature, vol. 420, no. 6917, pp. 860-867, 2002.
97. M. E. Tome, J. B. Frye, D. L. Coyle et al. , Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance, Experimental and Therapeutic Medicine, vol. 3, no. 5, pp. 845-852, 2012.
98. Z. Zhu, Z. Shen, and C. Xu, Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer,Mediators of Inflammation, vol. 2012,Article ID528690, 11 pages, 2012.
99. S. Deaglio, K. M. Dwyer, W. Gao et al. , Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression, The Journal of Experimental Medicine, vol. 204, no. 6, pp. 1257-1265, 2007.
100. A. Clayton, S. Al-Taei, J. Webber, M. D. Mason, and Z. Tabi, Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production, Journal of Immunology, vol. 187, no. 2, pp. 676-683, 2011.
101. A. Rimessi, E. Zecchini, R. Siviero et al. , The selective inhibition of nuclear PKCzeta restores the effectiveness of chemotherapeutic agents in chemoresistant cells, Cell Cycle, vol. 11, no. 5, pp. 1040-1048, 2012.
102. F. Balkwill, K. A. Charles, and A. Mantovani, Smoldering and polarized inflammation in the initiation and promotion of malignant disease, Cancer Cell, vol. 7, no. 3, pp. 211-217, 2005.
103. S. Delhalle, V. Deregowski, V. Benoit, M. -P. Merville, and V. Bours, NF-B-dependentMnSOD expression protects adenocarcinoma cells fromTNF-induced apoptosis, Oncogene, vol. 21, no. 24, pp. 3917-3924, 2002.
104. J. C. Cusack, R. Liu, and A. S. Baldwin, NF-kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappa B,Drug ResistanceUpdates, vol. 2, no. 4,pp. 271-273, 1999.
105. S. Cun?, P. Pérez-Aciego, G. Pérez-Chacón et al. , A sustained activation of PI3K/NF-B pathway is critical for the survival of chronic lymphocytic leukemia B cells, Leukemia, vol. 18, no. 8, pp. 1391-1400, 2004.
106. K. Schulze-Osthoff,M. K. A. Bauer,M. Vogt, and S. Wesselborg, Oxidative stress and signal transduction, International Journal for Vitamin and Nutrition Research, vol. 67, no. 5, pp. 336-342, 1997.
107. K. A. Manu, M. K. Shanmugam, L. Ramachandran et al. , Isorhamnetin augments the anti-tumor effect of capeciatbine through the negative regulation of NF-B signaling cascade in gastric cancer, Cancer Letters, vol. 363, no. 1, pp. 28-36, 2015.
108. M. Singh, K. Bhui, R. Singh, and Y. Shukla, Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis, Life Sciences, vol. 93, no. 1, pp. 7-16, 2013.
109. S. J. Talbott, S. Luanpitpong, C. Stehlik et al. , S-nitrosylation of FLICE inhibitory protein determines its interaction with RIP1 and activation of NF-B, Cell Cycle, vol. 13, no. 12, pp. 1948-1957, 2014.
110. X. Zhou, Z. Zhang, X. Yang,W. Chen, and P. Zhang, Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity, International Journal of Cancer, vol. 124, no. 2, pp. 483-489, 2009.
111. K. Husain, R. A. Francois, T. Yamauchi, M. Perez, S. M. Sebti, and M. P. Malafa, Vitamin E -tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-B activation in pancreatic cancer,Molecular CancerTherapeutics, vol. 10, no. 12, pp. 2363-2372, 2011.
112. B. B. Aggarwal, A. Kumar, and A. C. Bharti, Anticancer potential of curcumin: preclinical and clinical studies, Anticancer Research, vol. 23, no. 1, pp. 363-398, 2003.
113. Y. Hu, S. Wang, X. Wu et al. , Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma, Journal of Ethnopharmacology, vol. 149, no. 3, pp. 601-612, 2013.
114. Y. Kwon, Curcumin as a cancer chemotherapy sensitizing agent, Journal of the Korean Society for Applied Biological Chemistry, vol. 57, no. 2, pp. 273-280, 2014.
115. B. B. Aggarwal, I. D. Bhatt, H. Ichikawa et al. , Curcuminbiological and medicinal properties, in Turmeric the Genus Curcuma, P. N. Ravindran, K. N. Babu, and K. Sivaraman, Eds. , pp. 297-368, CRC Press, New York, NY, USA, 2007.
116. X. Xue, J. -L. Yu, D. -Q. Sun et al. , Curcumin as a multidrug resistance modulator-a quick review, Biomedicine & Preventive Nutrition, vol. 3, no. 2, pp. 173-176, 2013.
117. C. -L. Lin, R. -F. Chen, J. Y. -F. Chen et al. , Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-b pathway, International Journal ofMolecular Sciences, vol. 13, no. 5, pp. 6236-6245, 2012.
118. S. J. Klempner, A. P. Myers, and L. C. Cantley, What a tangled web we weave: emerging resistancemechanisms to inhibition of the phosphoinositide 3-kinase pathway, Cancer Discovery, vol. 3, no. 12, pp. 1345-1354, 2013.
119. A. Bellacosa, C. C. Kumar, A. D. Cristofano, and J. R. Testa, Activation of AKT kinases in cancer: implications for therapeutic targeting, Advances in Cancer Research, vol. 94, no. 1, pp. 29-86, 2005.
120. T. A. Yap, L. Bjerke, P. A. Clarke, and P. Workman, Drugging PI3K in cancer: refining targets and therapeutic strategies, Current Opinion in Pharmacology, vol. 23, pp. 98-107, 2015.
121. Z. Yu, G. Xie, G. Zhou et al. , NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells, Cancer Letters, vol. 367, no. 1, pp. 58-68, 2015.
122. T. Laragione, V. Bonetto, F. Casoni et al. , Redox regulation of surface protein thiols: identification of integrin alpha-4 as a molecular target by using redox proteomics, Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 25, pp. 14737-14741, 2003.
123. A. Layani-Bazar, I. Skornick, A. Berrebi et al. , Redox modulation of adjacent thiols in vla-4 by as101 converts myeloid leukemia cells from a drug-resistant to drug-sensitive state, Cancer Research, vol. 74, no. 11, pp. 3092-3103, 2014.
124. A. -M. Gao, Z. -P. Ke, J. -N. Wang, J. -Y. Yang, S. -Y. Chen, and H. Chen, Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway, Carcinogenesis, vol. 34, no. 8, pp. 1806-1814, 2013.
125. C. De Luca, Z. Kharaeva, and L. Korkina, Is there a role for antioxidants in the prevention of infection-associated carcinogenesis and in the treatment of infection-driven tumours? Current Topics in Medicinal Chemistry, vol. 15, no. 2, pp. 120-135, 2015.
126. M. G. Kelly, A. B. Alvero, R. Chen et al. , TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer, Cancer Research, vol. 66, no. 7, pp. 3859-3868, 2006.
127. S. Rajput, L. D. Volk-Draper, and S. Ran, TLR4 is a novel determinant of the response to paclitaxel in breast cancer, Molecular Cancer Therapeutics, vol. 12, no. 8, pp. 1676-1687, 2013.
128. S. Ioannou and M. Voulgarelis, Toll-like receptors, tissue injury, and tumourigenesis, Mediators of Inflammation, vol. 2010, Article ID 581837, 9 pages, 2010.
129. B. Huang, J. Zhao, S. Shen et al. , Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling, Cancer Research, vol. 67, no. 9, pp. 4346-4352, 2007.
130. T. Grimmig, N. Matthes, K. Hoeland et al. , TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer, International Journal of Oncology, vol. 47, no. 3, pp. 857-866, 2015.
131. M. Muccioli, L. Sprague, H. Nandigam, M. Pate, and F. Benencia, Toll-like receptors as novel therapeutic targets for ovarian cancer, ISRN Oncology, vol. 2012, Article ID 642141, 8 pages, 2012.
132. D. Kim, H. C. Dan, S. Park et al. , AKT/PKB signaling mechanisms in cancer and chemoresistance, Frontiers in Bioscience, vol. 10, pp. 975-987, 2005.
133. E. Tiligada, Chemotherapy: induction of stress responses, Endocrine-Related Cancer, vol. 13, supplement 1, pp. S115-S124, 2006.
134. D. Kultz, Molecular and evolutionary basis of the cellular stress response, Annual Review of Physiology, vol. 67, pp. 225-257, 2005.
135. M. Landriscina, F. Maddalena, G. Laudiero, and F. Esposito, Adaptation to oxidative stress, chemoresistance, and cell survival, Antioxidants & Redox Signaling, vol. 11, no. 11, pp. 2701-2716, 2009.
136. S. Singh, S. Vrishni, B. K. Singh, I. Rahman, and P. Kakkar, Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases, Free Radical Research, vol. 44, no. 11, pp. 1267-1288, 2010.
137. K. Shen, D. Cui, L. Sun,Y. Lu, M. Han, and J. Liu, Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression, Journal of Cellular Biochemistry, vol. 113, no. 6, pp. 2086-2097, 2012.
138. K. C. Wu, J. Y. Cui, and C. D. Klaassen, Effect of graded nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver, PLoS ONE, vol. 7, no. 7, Article ID e39006, 2012.
139. X. -J. Wang, Z. Sun, N. F. Villeneuve et al. , Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2, Carcinogenesis, vol. 29, no. 6, pp. 1235-1243, 2008.
140. X. Tang,H. Wang, L. Fanet al. , Luteolin inhibitsNrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs, Free Radical Biology & Medicine, vol. 50, no. 11, pp. 1599-1609, 2011.
141. D. Ren, N. F. Villeneuve, T. Jiang et al. , Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism, Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 4, pp. 1433-1438, 2011.
142. M. Zhang, C. Zhang, L. Zhang et al. , Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma, BMC Cancer, vol. 15, article 531, 2015.
143. Y. J. Lee, D. M. Lee, and S. H. Lee, Nrf2 expression and apoptosis in quercetin-treated malignant mesothelioma cells, Molecules and Cells, vol. 38, no. 5, pp. 416-425, 2015.
144. L. Zhan, H. Zhang, Q. Zhang et al. , Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells, Free Radical Biology and Medicine, vol. 53, no. 4, pp. 758-768, 2012.
145. Y. Soini, M. Eskelinen, P. Juvonen et al. , Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma, Pathology Research and Practice, vol. 210, no. 1, pp. 35-39, 2014.
146. A. J. León-González, C. Auger, and V. B. Schini-Kerth, Prooxidant activity of polyphenols and its implication on cancer chemoprevention and chemotherapy, Biochemical Pharmacology, vol. 98, no. 3, pp. 371-380, 2015.
147. D. Kandioler-Eckersberger, C. Ludwig, M. Rudas et al. , TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients, Clinical Cancer Research, vol. 6, no. 1, pp. 50-56, 2000.
148. A. L. Furfaro, S. Piras, M. Passalacqua et al. , HO-1 upregulation: a key point in high-risk neuroblastoma resistance to bortezomib, Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1842, no. 4, pp. 613-622, 2014.
149. M. Lee, D. -H. Hyun, K. -A. Marshall et al. , Effect of overexpression of Bcl-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome, Free Radical Biology andMedicine, vol. 31, no. 12, pp. 1550-1559, 2001.
150. D. M. Hockenbery, Z. N. Oltvai, X. -M. Yin, C. L. Milliman, and S. J. Korsmeyer, Bcl-2 functions in an antioxidant pathway to prevent apoptosis, Cell, vol. 75, no. 2, pp. 241-251, 1993.
151. D. W. Voehringer, BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity, Free Radical Biology and Medicine, vol. 27, no. 9-10, pp. 945-950, 1999.
152. S. L. Schendel, Z. Xie, M. O. Montal, S. Matsuyama,M. Montal, and J. C. Reed, Channel formation by antiapoptotic protein Bcl-2, Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 10, pp. 5113-5118, 1997.
153. J. L. Herrmann, E. Bruckheimer, and T. J. McDonnell, Cell death signal transduction and Bcl-2 function, Biochemical Society Transactions, vol. 24, no. 4, pp. 1059-1065, 1996.
154. L. Chaiswing, J. M. Bourdeau-Heller, W. Zhong, and T. D. Oberley, Characterization of redox state of two human prostate carcinoma cell lines with different degrees of aggressiveness, Free Radical Biology and Medicine, vol. 43, no. 2, pp. 202-215, 2007.
155. L. H. Lash, D. A. Putt, and A. D. Jankovich, Glutathione levels and susceptibility to chemically induced injury in two human prostate cancer cell lines, Molecules, vol. 20, no. 6, pp. 10399-10414, 2015.
156. J. Niestroy, A. Barbara, K. Herbst, S. Rode, M. van Liempt, and P. H. Roos, Single and concerted effects of benzo[a]pyrene and flavonoids on the AhR and Nrf2-pathway in the human colon carcinoma cell line Caco-2, Toxicology in Vitro, vol. 25, no. 3, pp. 671-683, 2011.
157. H. I. Swanson, Cytochrome P450 expression in human keratinocytes: an aryl hydrocarbon receptor perspective, Chemico-Biological Interactions, vol. 149, no. 2-3, pp. 69-79, 2004.
158. A. Rannug and E. Fritsche, The aryl hydrocarbon receptor and light, Biological Chemistry, vol. 387, no. 9, pp. 1149-1157, 2006.
159. D. W. Nebert, A. L. Roe,M. Z. Dieter,W. A. Solis,Y. Yang, andT. P. Dalton, Role of the aromatic hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle control, and apoptosis, Biochemical Pharmacology, vol. 59,no. 1, pp. 65-85, 2000.
160. L. Stejskalova, Z. Dvorak, and P. Pavek, Endogenous and exogenous ligands of aryl hydrocarbon receptor: current state of art, CurrentDrugMetabolism, vol. 12,no. 2, pp. 198-212, 2011.
161. E. S. Shen and J. P. Whitlock Jr. , Protein-DNA interactions at a dioxin-responsive enhancer: mutational analysis of the DNAbinding site for the liganded Ah receptor, The Journal of Biological Chemistry, vol. 267, no. 10, pp. 6815-6819, 1992.
162. S. Kalthoff, U. Ehmer, N. Freiberg, M. P. Manns, and C. P. Strassburg, Intercation between oxidative stress sensor Nrf2 and xenobiotic-activated aryl hydrocarbon receptor in the regulation of the human phase II detoxifying UDP-glucuronosyltransferase 1A10, The Journal of Biological Chemistry, vol. 285, no. 9, pp. 5993-6002, 2010.
163. R. L. Yeager, S. A. Reisman,L. M. Aleksunes, andC. D. Klaassen, Introducing the TCDD-inducible AhR-Nrf2 gene battery, Toxicological Sciences, vol. 111, no. 2, pp. 238-246, 2009.
164. H. I. Swanson and C. A. Bradfield, TheAH-receptor: genetics, structure and function, Pharmacogenetics, vol. 3, no. 5, pp. 213-230, 1993.
165. T. Haarmann-Stemmann, H. Bothe, and J. Abel, Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways, Biochemical Pharmacology, vol. 77, no. 4, pp. 508-520, 2009.
166. Q. Ma, Influence of light on aryl hydrocarbon receptor signaling and consequences in drug metabolism, physiology and disease, Expert Opinion on Drug Metabolism and Toxicology, vol. 7, no. 10, pp. 1267-1293, 2011.
167. A. Puga, C. Ma, and J. L. Marlowe, The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways, Biochemical Pharmacology, vol. 77, no. 4, pp. 713-722, 2009.
168. C. M. Klinge, K. Kaur, and H. I. Swanson, The aryl hydrocarbon receptor interacts with estrogen receptor alpha and orphan receptors COUP-TFI and ERR 1, Archives of Biochemistry and Biophysics, vol. 373, no. 1, pp. 163-174, 2000.
169. F. Ohtake, K. -I. Takeyama, T. Matsumoto et al. , Modulation of estrogen receptor signaling by association with the activated dioxin receptor, Nature, vol. 423, no. 6939, pp. 545-550, 2003.
170. E. Guyot, A. Chevallier, R. Barouki, and X. Coumoul, The AhR twist: ligand-dependent AhR signaling and pharmacotoxicological implications, Drug Discovery Today, vol. 18, no. 9-10, pp. 479-486, 2013.
171. M. A. Callero andA. I. Loaiza-Pérez, The role of aryl hydrocarbon receptor and crosstalkwith estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone, International Journal of Breast Cancer, vol. 2011, Article ID 923250, 9 pages, 2011.
172. H. Eguchi, T. Ikuta, T. Tachibana, Y. Yoneda, and K. Kawajiri, A nuclear localization signal of human aryl hydrocarbon receptor nuclear translocator/hypoxia-inducible factor 1 is a novel bipartite type recognized by the two components of nuclear pore-targeting complex, The Journal of Biological Chemistry, vol. 272, no. 28, pp. 17640-17647, 1997.
173. Y. Kanno, Y. Miyama, Y. Takane, T. Nakahama, and Y. Inouye, Identification of intracellular localization signals and of mechanisms underlining the nucleocytoplasmic shuttling of human aryl hydrocarbon receptor repressor, Biochemical and Biophysical Research Communications, vol. 364, no. 4, pp. 1026-1031, 2007.
174. P. S. Wong,W. Li, C. F. Vogel, and C. F. Matsumura, Characterization of MCF mammary epithelial cells overexpressing the Arylhydrocarbon receptor (AhR), BMC Cancer, vol. 9, article 234, pp. 234-10, 2009.
175. G. D. Goode, B. R. Ballard, H. C. Manning, M. L. Freeman, Y. Kang, and S. E. Eltom, Knockdown of aberrantly upregulated aryl hydrocarbon receptor reduces tumor growth and metastasis of MDA-MB-231 human breast cancer cell line, International Journal of Cancer, vol. 133, no. 12, pp. 2769-2780, 2013.
176. G. Goode, S. Pratap, and S. E. Eltom, Depletion of the aryl hydrocarbon receptor in MDA-MB-231 human breast cancer cells altered the expression of genes in key regulatory pathways of cancer, PLoS ONE, vol. 9, no. 6,Article ID e100103, 2014.
177. L. Partanen, J. Staaf, M. Tanner, V. J. Tuominen, ? A. Borg, and J. Isola, Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer,Genes Chromosomes and Cancer, vol. 51, no. 9, pp. 832-840, 2012.
178. C. OBrien, G. Cavet, A. Pandita et al. , Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer, Cancer Research, vol. 68, no. 13, pp. 5380-5389, 2008.
179. D. Caccamo, E. Cesareo, S. Mariani et al. , Xenobiotic sensor-and metabolism-related gene variants in environmental sensitivity-related illnesses: a survey on the Italian population, Oxidative Medicine and Cellular Longevity, vol. 2013,Article ID 831969, 9 pages, 2013.
180. S. Helmig, J. U. Seelinger, J. Döhrel, and J. Schneider, RNA expressions ofAHR,ARNT and CYP1B1 are influenced byAHR Arg554Lys polymorphism,MolecularGenetics andMetabolism, vol. 104, no. 1-2, pp. 180-184, 2011.
181. P. B. Busbee, M. Rouse, M. Nagarkatti, and P. S. Nagarkatti, Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders, Nutrition Reviews, vol. 71, no. 6, pp. 353-369, 2013.
182. V. Kostyuk, A. Potapovich, A. Stancato et al. , Photo-oxidation products of skin surface squalene mediate metabolic and inflammatory responses to solar UV in human keratinocytes, PLoS ONE, vol. 7, no. 8,Article ID e44472, 2012.
183. S. Pastore, D. Lulli, P. Fidanza et al. , Plant polyphenols regulate chemokine expression and tissue repair in human keratinocytes through interaction with cytoplasmic and nuclear components of epidermal growth factor receptor system, Antioxidants and Redox Signaling, vol. 16, no. 4, pp. 314-328, 2012.
184. A. I. Potapovich, D. Lulli, P. Fidanza et al. , Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NF B and AhR and EGFR-ERK pathway, Toxicology and Applied Pharmacology, vol. 255, no. 2, pp. 138-149, 2011.
185. J. -F. Savoure, M. Antenos, M. Quesne, J. Xu, E. Milgrom, and R. F. Casper, 7-ketocholesterol is an endogenous modulator for the arylhydrocarbon receptor, Journal of Biological Chemistry, vol. 276, no. 5, pp. 3054-3059, 2001.
186. A. Wilhelmsson, M. L. Whitelaw, J. -A. Gustafsson, and L. Poellinger, Agonistic and antagonistic effects of -naphthoflavone on dioxin receptor function: role of the basic region helix-loop-helix dioxin receptor partner factor arnt, The Journal of Biological Chemistry, vol. 269, no. 29, pp. 19028-19033, 1994.
187. S. -H. Kim, E. C. Henry, D. -K. Kim et al. , Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor, Molecular Pharmacology, vol. 69, no. 6, pp. 1871-1878, 2006.
188. J. -E. Lee and S. Safe, 3 , 4 -dimethoxyflavone as an aryl hydrocarbon receptor antagonist in human breast cancer cells, Toxicological Sciences, vol. 58, no. 2, pp. 235-242, 2000.
189. I. A. Murray, C. A. Flaveny, B. C. DiNatale et al. , Antagonism of aryl hydrocarbon receptor signaling by 6,2 ,4 -trimethoxyflavone, Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 1, pp. 135-144, 2010.
190. Y. -F. Lu,M. Santostefano, B. D. M. Cunningham,M. D. Threadgill, and S. Safe, Identification of 3 -methoxy-4 -nitroflavone as a pure aryl hydrocarbon (Ah) receptor antagonist and evidence for more than one form of the nuclear Ah receptor in MCF-7 human breast cancer cells, Archives of Biochemistry and Biophysics, vol. 316, no. 1, pp. 470-477, 1995.